Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Dendreon
 More »

  • Dendreon Gets Green Light in Europe
    Dendreon said today its prostate cancer drug Provenge® (autologous peripheral blood ... Last month, Dendreon reported about $73 million in Q2 sales, up from Q1 but below analyst ...
    9-17-2013
  • Vaccine Advances Drive Differentiation
    ... the U.S. government," Hedegaard added. "Approval is pending in Canada and the EU." Dendreon focuses on activated cellular immunology, having developed Provenge as a treatment ...
    6-1-2013
  • Cancer's Bitter Medicine
    ... from the decade-ago average of $5,000. Dendreon raised eyebrows in 2010 when it launched ... Dendreon defends its pricing by citing its drug as a first-in-class, personalized ...
    5-21-2013
  • Bayer Prostate Cancer Drug Gains FDA Approval
    Bayer HealthCare said yesterday it is weeks away from joining Algeta in bringing to the U.S. market their advanced prostate cancer drug Xofigo® (radium Ra 223 dichloride) ...
    5-16-2013
  • GEN | Biolinks
    ... Institute Delaware Economic Development Office Delaware State University Dendreon Dengue Vaccine Initiative Deutsche Industrievereinigung Biotechnologie (DIB) ...
  • Dendreon, Plaintiffs Settle Class-Action Suit for $40M
    Dendreon said today it signed off on a $40 million securities class-action settlement to ... In a statement, Dendreon and three current and former executive officers named as ...
    3-18-2013
  • Top 10 Biopharma Layoffs of 2012
    ... Pfizer took $529 million in restructuring charges during Q4 2012 for "cost-reduction and productivity initiatives." 10. Dendreon Total workforce reduction: More than 500 full-time ...
    3-15-2013
  • Rise of Cell-Based Immunotherapy
    therapeutic cancer vaccine has been approved by the U.S. FDA-this is Provenge® from Dendreon, an autologous antigen-pulsed dendritic cell-based cancer vaccine designed to ...
    3-1-2013
  • Dendreon Profits Shrink Despite Product Revenue Gain
    Dendreon today said it finished the fourth quarter of 2012 with a net loss that continued ... For all of 2012, Dendreon finished with a net loss of $393.6 million or $2.65 per share, ...
    2-25-2013
  • Top 10 Biopharma Layoffs of 2012
    occurrence, projected savings, and costs and charges attributed to the layoffs. #10. Dendreon Total workforce reduction: More than 500 full-time and contractor jobs, primarily ...
    2-15-2013
  • Troubled Dendreon Sells Off NJ Plant
    Dendreon today said it sold to Novartis its immunotherapy manufacturing facility in Morris ... a year of weaker-than-expected sales. "Dendreon continues to make progress in improving ...
    12-20-2012
  • Biotech: A Model of Creative Acquisition
    ... The next three largest U.S. public biopharmaceutical companies-Regeneron, Onyx, and Dendreon-reported total revenues over $1.2 billion in 2011, increasing 1,700% from $67 million ...
    12-1-2012
  • Getting Cancer Immunotherapeutics Approved
    It's not just the FDA standing in the way. While biologically based therapeutic cancer vaccines and other cancer immunotherapies have great promise in treating certain cancers, ...
    11-13-2012
  • Cervical Cancer Vaccine Funded
    lasting immune response at a lower dose than traditional vaccines. Secondly, unlike Dendreon, there is no need to extract patient cells, rather we just use a simple DNA or ...
    11-12-2012
  • Majority Sees BiovaxID Gaining Faster Acceptance if Approved...
    will not face the manufacturing and reimbursement issues Dendreon has had to deal with. ... production time frames are not as limited as those of Dendreon. | Alex Philippidis
    8-23-2012

  • Journal Articles

  • Steady Advance of Stem Cell Therapies: Report from the 2011 World...
    Melanie Swan
    Rejuvenation Research
    Steady Advance of Stem Cell Therapies: Report from the 2011 World Stem Cell Summit, Pasadena, California, October 3-5 Rejuvenation Research Abstract Stem cell research and related ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll